ON102

**ON102** is an investigational **radiolabeled monoclonal antibody diagnostic** being developed by **OncoOne** for oncology imaging and patient selection. The agent is designed to bind **oxidized macrophage migration inhibitory factor**, the disease-associated isoform known as **oxMIF**, which is reported to be selectively present in diseased tissue and implicated in immune-evasive and immune-tolerant tumor biology. ON102 is positioned as a companion diagnostic for OncoOne's oxMIF-directed therapeutic program **ON203**, with intended application across solid tumors including **colorectal cancer, lung cancer, pancreatic cancer, and ovarian cancer**. Based on the provided context, the program was partnered with **GenScript ProBio** for manufacturing and was planned to enter **Phase 1** clinical testing in 2023.

Other names

oxMIF-targeting radiolabeled monoclonal antibody diagnostic